Get the Stockscreener App
3.40
3.34%
+0.11
Pre-market:
3.37
-0.03
-0.88%
Revance Therapeutics Inc stock is currently priced at $3.40, with a 24-hour trading volume of 2.27M.
It has seen a +3.34% increased in the last 24 hours and a -27.66% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.34 pivot point. If it approaches the $3.45 resistance level, significant changes may occur.
Previous Close:
$3.29
Open:
$3.36
24h Volume:
2.27M
Market Cap:
$354.33M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
-0.7506
EPS:
-4.53
Net Cash Flow:
$-223.46M
1W Performance:
-10.05%
1M Performance:
-27.66%
6M Performance:
-57.18%
1Y Performance:
-89.21%
1D Range:
$3.21
$3.56
52W Range:
$3.21
$37.98
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
510-742-3400
Address
7555 Gateway Boulevard, Newark, CA
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Benzinga
GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Benzinga
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revance Therapeutics Inc (RVNC) Revenue 2024
RVNC reported a revenue (TTM) of $234.04 million for the quarter ending December 31, 2023, a +76.55% rise year-over-year.
Revance Therapeutics Inc (RVNC) Net Income 2024
RVNC net income (TTM) was -$323.92 million for the quarter ending December 31, 2023, a +9.20% increase year-over-year.
Revance Therapeutics Inc (RVNC) Cash Flow 2024
RVNC recorded a free cash flow (TTM) of -$223.46 million for the quarter ending December 31, 2023, a -13.57% decrease year-over-year.
Revance Therapeutics Inc (RVNC) Earnings per Share 2024
RVNC earnings per share (TTM) was -$3.80 for the quarter ending December 31, 2023, a +21.00% growth year-over-year.
About Revance Therapeutics Inc
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
1.53%
3.38%
Cap:
|
Volume (24h):